QNRX Quoin Pharmaceuticals, Ltd. Stock Quote

QNRX [NASD]

Index	-	P/E	-	EPS (ttm)	-	Insider Own	17.47%	Shs Outstand	8.35M	Perf Week	-15.56%
Market Cap	3.16M	Forward P/E	-	EPS next Y	-13.33	Insider Trans	0.00%	Shs Float	5.37M	Perf Month	-7.90%
Income	-4.90M	PEG	-	EPS next Q	-3.08	Inst Own	11.20%	Short Float	1.39%	Perf Quarter	-39.41%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-1.32%	Short Ratio	0.05	Perf Half Y	-72.64%
Book/sh	267.43	P/B	0.02	EPS next Y	-	ROA	-79.70%	Target Price	52.03	Perf Year	-97.58%
Cash/sh	3.88	P/C	1.22	EPS next 5Y	-	ROE	-106.40%	52W Range	3.58 - 444.00	Perf YTD	-79.25%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-98.94%	Beta	1.66
Dividend %	-	Quick Ratio	3.00	Sales past 5Y	-	Gross Margin	-	52W Low	31.84%	ATR	2.60
Employees	4	Current Ratio	3.00	Sales Q/Q	-	Oper. Margin	-	RSI (14)	46.27	Volatility	20.99% 50.26%
Optionable	No	Debt/Eq	0.12	EPS Q/Q	63.80%	Profit Margin	-	Rel Volume	0.59	Prev Close	4.78
Shortable	Yes	LT Debt/Eq	0.06	Earnings	-	Payout	-	Avg Volume	1.47M	Price	4.72
Recom	-	SMA20	-23.30%	SMA50	-21.20%	SMA200	-80.41%	Volume	865,818	Change	-1.26%

Aug-11-22 04:30PM	Quoin Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 18th GlobeNewswire
Aug-09-22 04:23PM	Quoin Pharmaceuticals Announces Closing of $16.8 Million Public Offering GlobeNewswire -8.77%
Aug-05-22 09:28AM	Quoin Pharmaceuticals Announces Pricing of $16.8 Million Upsized Public Offering GlobeNewswire -62.38%
Jul-28-22 08:30AM	Quoin Pharmaceuticals Announces Receipt of Constructive Scientific Advice from EMA for QRX003 Development in Europe GlobeNewswire
Jul-18-22 11:43AM	Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada Zacks
Jul-15-22 08:30AM	Quoin Pharmaceuticals and Endo Ventures Limited Enter Into Exclusive Distribution and Supply Agreements GlobeNewswire -12.75%
07:30AM	Endo Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in Canada PR Newswire
Jul-06-22 08:30AM	Quoin Pharmaceuticals Announces Opening of First Clinical Site for Netherton Syndrome Clinical Study GlobeNewswire +13.18%
Jun-15-22 04:01PM	Quoin Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement GlobeNewswire -14.60%
08:30AM	Quoin Pharmaceuticals Announces Licensing and Distribution Agreement with Leading Rare Disease Company for Greater China GlobeNewswire
Jun-14-22 08:30AM	Quoin Pharmaceuticals: Strategically Building For Future Success Newsfile +6.02%
Jun-10-22 10:23AM	15 Best Penny Stocks To Invest In Insider Monkey
Jun-06-22 11:22AM	Why Are Quoin Pharma Shares Trading Higher Today? Benzinga -7.50%
08:00AM	Skinvisible Announces First Invisicare Delivery Technology Product to Receive U.S. FDA Acceptance of Investigational New Drug ACCESSWIRE
May-23-22 08:30AM	Quoin Pharmaceuticals Enters Exclusive Research Agreement for Scleroderma Treatment with Australian University GlobeNewswire
May-17-22 08:30AM	Quoin Pharmaceuticals: On Track to Deliver the First FDA-Approved Treatment for Netherton Syndrome Newsfile +12.64%
May-11-22 11:24AM	When Will Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Breakeven? Simply Wall St. -8.48%
Apr-25-22 01:05PM	QNRX: FDA Clearance To Move QRX003 Clinical Testing Forward; Positive Implications Zacks Small Cap Research +10.00%
08:30AM	Quoin Pharmaceuticals Announces FDA Clearance of IND for its Lead Asset, QRX003, for Netherton Syndrome GlobeNewswire
Mar-24-22 08:30AM	Quoin Pharmaceuticals Targeting Regulatory Approvals for Lead Candidate for Netherton Syndrome in 2024 Newsfile
Mar-15-22 08:41AM	Quoin Pharmaceuticals Announces Submission of IND for its Lead Asset, QRX003, for Netherton Syndrome GlobeNewswire
Mar-10-22 08:00AM	Quoin Pharmaceuticals Submits Scientific Advice Briefing Document to EMA for its Lead Asset, QRX003, for Netherton Syndrome GlobeNewswire +14.34%
Mar-01-22 08:00AM	Quoin Pharmaceuticals Extends Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome GlobeNewswire +5.41%
Feb-17-22 08:00AM	Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Neopharm for its Lead Asset, QRX003, for Netherton Syndrome GlobeNewswire
Feb-10-22 08:00AM	Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome GlobeNewswire
Feb-08-22 08:30AM	Changing Lives, Delivering Value: Quoin Pharmaceuticals is Making the Balancing Act Look Easy Newsfile
Jan-26-22 08:00AM	Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with OrphanDC for its Lead Asset, QRX003, for Netherton Syndrome GlobeNewswire -6.52%
Jan-24-22 07:15AM	QNRX: Laying the Groundwork to Launch Multiple Treatments for Rare & Orphan Diseases Zacks Small Cap Research
Dec-15-21 09:00AM	Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Orpharm LLC for its Lead Asset, QRX003, for Netherton Syndrome GlobeNewswire -12.58%
Dec-14-21 08:30AM	The R&D Sweet Spot: Quoin Pharmaceuticals Delivering Value-Based Drug Development Through Rare and Orphan Disease Therapeutics Newsfile
Nov-16-21 08:30AM	Quoin Pharmaceuticals Poised for Rapid Commercialization of Promising Pipeline Newsfile
Nov-11-21 08:30AM	Quoin Pharmaceuticals and Genpharm Services Sign Exclusive License and Distribution Agreement for Quoins Lead Asset, QRX003 GlobeNewswire -21.74%
Nov-08-21 08:00AM	Quoin Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with AFT Pharmaceuticals for its Lead Asset, QRX003 GlobeNewswire -8.94%
Nov-04-21 09:25AM	Quoin Pharmaceuticals Appoints Gordon Dunn as Chief Financial Officer GlobeNewswire
Nov-02-21 08:30AM	Quoin Pharmaceuticals Announces Signing of Exclusive License from Queensland University of Technology, Australia GlobeNewswire

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience